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of quality in health care delivery through increased and data-driven 
preventive efforts. Applied epidemiological and &cal research to- 
gether with teaching of health care workers are key components of 
this strategy. If European hospital epidemiologists and infectious dis- 
eases specialists join forces in this field, we can indeed do better. 
Trends in nosocomial infections in Europe: 
Comparison between Westem and Central 
Europe 
V &&dry, Jr.. University of Enaua, Dept. ofMedicine Slovak 
Republic, Slovakia 
In 1970-1990 in Western Europe expansion of medical technology 
was marked. In addition, medium age in Western Europe and Scan- 
dinavia increased. This both caused an marked increase of number of 
hospitalized patients treated with invasive procedures and geriatric 
population. More clinically ill patients with previously incurable 
diseases (Leukemias, renal, hepatic fdures, cystic fibrosis) survived 
due to invasive diagnostic and therapeutic procedures: This logic 
increase of nosocomial bacterial (ventillatory pneumonia, catheter 
related bacterias), wal (BMT-related late d infections) fungal 
(hematologic neoplasias) or parasitic (AIDS-related) nosocormal in- 
fections appeared. In contrast to &IS, socio-economic situation in 
health care in Central/Eastern Europe (CEE) until 1990 was not 
affected with new expensive medical technologies and majority of 
nosocomial infections appeared after major or trauma surgery and in 
neonatal intensive care medicine. After political changes and open- 
ing borders, medical technology improved communications: e.g. no 
of BMT centers in CEE increased h m  9 to 85 (in 1995) and 
no of dialysis increased h m  approx 200 to more than 1500. Also 
the number of patients with liver transplants increped tenfold and 
lung transplants fivefold in comparison to 1990. In etiology, increase 
of grampositive bacteremia and fungi was detected. However, In- 
cidence of VR enterococci is still 0-2% in comparison to Western 
Europe, but resistance in staphylococci to oxacillin and Ps. aerugi- 
nosa to aminoglycosides is higher than in Western Europe. 
Nosocomial Infections in HIV Patients 
E. Bouza. E 
No absaact available 
Multi-R strains in hospitals: should we control 
them or live with them? 
B. Regnier. Bichat-Claude Hospital, Paris, France 
Although the threat of antimicrobial resistance has been repeatedly ad- 
dressed, it is obvious that epidemiological trends reported &om many 
countries reflect a poor implementation of the control measures. In 
fact, some authorities still question the relevance of such programs. It 
is therefore necessary to better delineate the impact ofmulti-R strains 
in hospitals and justify these expensive and time-consuming strategies. 
Several effects of a high rate antimicrobial resistance are documented 
such as an increased use of newhroad spectrum antibiotics. Ths, 
in turn, results in the emergence of new mechanisms of resistance 
and high costs. Transfer or readmission of colonized patients results 
in the Musion of R-strains to other hospitals or care-facilities and 
occasionally to other countries. F d y ,  hospital costs and workload 
ofhealth care workers are increased as a result ofisolation precautions. 
However, it is likely that some other impact of R-strains have been 
overlooked such as the relationship between antimicrobial-resistance 
and the severity and the incidence of nosocomial infections (NI). Of 
particular interest are several evidence strongly suggesting that high 
prevalence of R-strains could result in an increased the incidence 
of NI. They include: 1) epidemiological reports whch have docu- 
mented a rise in NI-rate following the introduction of R-strains in 
hospitals, 2) numerous clusters of R-strains-related NI superimposing 
to baseline attack rate, 3) some large prevalence studies have found 
a close association between NI and antimicrobial resistance rates 
throughout hospitals and countries, 4) despite susceptible strains are 
not less virulent it is striking that the R/S/ ratio is much more higher 
among NI isolates as compared with patients flora, 5) the occurrence 
of R-strains has been often incriminated in the failure of previously 
effective prophylactic regimen (surgery, SDD ...), 6) the probability of 
infection following colonization is higher for R-strains as compared 
with S-strains. The most likely explanation for these observations 
is that antibiotics given to 3 W O %  of hospitalized patients (6MO% 
in ICUs) leads to an untoward prophylaxis of NI only in patients 
not colonized with R-strains. In conclusion a high prevalence of 
multi-R-strains is probably and independent risk factor for NI. This, 
in addition to the non-quality sigdcation of cross colonization 
with R-strains, strongly supports the vigorous implementation of 
antimicrobial resistance control in hospitals. 
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Treatment of HIV Seroconversion 
L. Perrin, G. Schockmel, S. Yerly, B. Hirschel. Division ofhfectiouc 
Diseases, Geneva University Hospital, Geneva, Switzerland 
There is mounting evidence that clinical, virological and immuno- 
logical events occurring at the time of seroconversion govern the 
subsequent course of the infection. Ths and new data on patho- 
genesis demonstrating that HIV replication is active throughout the 
course of the dection support antiviral therapy starting as soon as 
the infection is detected. 
Several therapeutic trials using combined therapy (2 reverse tran- 
scriptase inhibitors @TI) or 2 RTI in combination with antiprotease), 
have induced in a majority of patients enrolled, a drop of viremia to 
undetectable levels (less than 200 HIV-1 RNA copiedml). By us- 
ing a mo&ed assay for viremia with a detection limit of around 10 
copiedml, we have shown that a number of patients had viremia lev- 
els between 10 and 200 copies/ml, 6 to 15 months after initiation of 
treatment. However, lymphoid organs are the main site ofviral storage 
and replication. Thus, analysis of lymph node biopsies might provide 
more in depth information on treatment efficacy. 
In this context, preliminary data in patients with viremia lower 
than 10 HIV RNA copies/ml shows an absence of viral deposits and 
no evidence of viral replication in lymph nodes. In contrast, patients 
with residual low viremia levels have incomplete clearance of viral 
deposits and low viral replication in lymph nodes. 
Concomitant analysis of viral load in blood and lymph nodes 
might help to evaluate therapeutic efficacy and to define guidehes 
for treatment (interruption of treatment, change in treatment or 
introduction of a simplified long-term maintenance therapy). 
15911 Which drugs for which patients? 
AJ. Pinching. St. Bartholomew’s and fhe Royal London School .f 
Medicine and Dentistry, London, UK 
Over the past year, there has been a radical change in the approach to 
anti-retroviral therapy in HIV-infected patients. Several new agents 
have become available. Many clinical trials have indicated that com- 
bination therapy with three or more agents will more profoundly 
and durably suppress viral replication. Viral load measures using PCR 
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have been shown to have clear prognostic value in untreated patients 
and to offer tools for monitoring ongoing therapeutic efficacy. 
These changes have produced optimism regardmg the longer term 
management of HIV and the application of these new finding in 
clinics has been rapid. Pending more definitive trial results, patients 
and clinicians need to develop skills in strategic planning of such 
therapies, and in their refinement as new events and data arise. 
T h  presentation will ou the  some principles regardmg critical 
treatment choices: when to start? what to start? what to star t?  why 
and when to change? what to change to? when and why to stop? 
These seek to be simple and practical, and can to shaped to patient 
and chic ian preferences, and in the light of new data. 
The Role of Resistance and Dynamics of HIV in 
Antiviral Therapy 
D.D. Richman. University of Calgornia San Diego and Sun Diego 
Weram Afiirs Medical Center, LOJolla, c4, USA 
Progress in our understanding of the dynamics of HIV replication 
and of HIV drug resistance are providing fundamental new insights 
into the pathogenesis of HIV infection and an increasingly ratio- 
nal approach to its effective chemotherapy. The source of plasma 
virus, its relationship to loss of immune function, the magnitude of 
virus replication and the turnover rates of virus pools are becoming 
defined and provide parameters for chemotherapeutic intervention. 
The rates of generation of genetic variants, the pre-existence of re- 
sistant mutan$ and the factors needed to suppress the emergence 
of drug resistance are also becoming defined to guide chemothera- 
peutic strategies. These insigha and the unresolved issues requiring 
further clarfication will be summarized in this presentation. 
Future Targets for HIV Antiviral Therapy 
J.€? Levy. F 
No abstract available. 
Innovative strategies for prevention and 
treatment of septic shock 
(Joint symposium with the European Society 
of Intensive Care Medicine) 
Neutralization of Bacterial Products: 
Crossreactive Anti-LPS Monoclonal Antibodies 
E.Th. Rietschel, EE. di Padova, R. Barclax H. Brade, 
D. Heumann. Research Center Bontel, CenterJor Medicine and 
Biosciences, 0-23845 Borstel, Germany 
Bacterial components such as endotoxins, exotoxins, peptidoglycan, 
lipoteichoic acid, and lipoprotein express a variety of biological ef- 
fects in lugher organisms. Among these components, endotoxins 
(hpopolysaccharides, LPS) are of particular biomedical importance. 
They not only constitute the 0-antigens of Gram-negative bacteria 
but are also essenhal for microbial viabikty and play an important 
role in the pathogenesis and toxic manifestations of bacterial infec- 
tion. Chemical characterization of Merent LPS have revealed com- 
mon structural features. The inner core region of LPS shows a high 
degree of similarity among Escherichia wli, Salmonella enterica, and 
Shigella serotypes. Among a large number of broadly crossreactive 
murine anti-core LPS Mab one of these (WN1 222-5; IgG2ak) has 
been selected and chimerized into a human IgGlk (SDZ 219-800). 
In ELISA and in immunoblots on purified LPS both SDZ 219-800 
and WNl 222-5 show a strong reactivity with all smooth LPS from 
E. roli and S. entm'ca semtypes. SDZ 219-800 and WNl 222-5 in- 
hibit in uivo the release of IL-6 and TNF and then neutralize the 
pyrogenic activity of E. coli LPS and protect mice from lethality. 
In addition, both Mab exhibit protective activity in a murine E .  
coli 0111 mfection model. Due to their broad reactivity and neu- 
aaliang characteristics these Mab represent potential candidates for 
immunotherapy of patients sutfering from endotoxemia and sepsis. 
)595/ The Therapeutic Role of G-CSF in Severe 
Infections in Non-Neutropenic Patients: Current 
Status and Future Prospects 
R.K. Root. Univ. of Wash., Seanle, WA, U S A  
G-CSF is a myelopoietic colony stimulating factor that is spe- 
d i c  for granulocytes. Administration of rGCSF (Filgrastim) to 
non-neutropenic subjects can expand the granulocyte (PMN) pool 
by almost 10-fold and can enhance the microbicidal functions of 
PMNs. Successful results in non-neutropenic animal models of in- 
fection, including sepsis and septic shock, have led to clinical studies 
of the utility of Filgrastim as an adjunct to antunicrobial therapy in 
patients with communiry acquired pneumonia (CAP), nosocomial 
pneumonia, neonatal sepsis, or systemic fungal infections. 
Results A large (756 patients) s t u d y  in patients with CAP has 
been completed. Mortality was low (6%) in both treated and placebo 
groups. Not only was Filgrastim well tolerated, but the incidence of 
organ failures, includmg ARDS, DIC and septic shock was sign& 
candy reduced as well as empyemas. Muldobar pneumonia patients 
had reduced lengths of stay in the ICU and more rapid resolution of 
infiltrates. 
Conclusions: Filgrastim administration to nonneutropenic pa- 
tients with CAP is safe and reduced infectious complications. Cur- 
rent studies focus on patients with pneumonia and septic shock or 
those with multilobar CAP to better define the patient groups most 
likely to benefit from G-CSF therapy. 
Is96/ Cytokine Manipulation in Patients with Sepsis 
J. Cohen. Department oflnferous Diseases, Rqal Postgraduate Medic51 
Srhool, London, UK 
Objectives: To critically review the current status of clinical trials in 
sepsis involving manipulation of the cyrokine cascade. Data Analysis: 
Despite the large amount of predinical data implicating cytokines as 
important medntors of sepsis, early clinical t rds  were driappoint- 
ing and led to considerable pessimism that cytokine-based strategies 
would ever have a chid role. Although it is still too soon to be 
sure, emerging data h m  the NORASEPT/INTERSEFT studtes 
and from the trial of the p 5 5 - s T m  suggest that a more encour- 
aging view m y  be justified. A crucial question will be whether 
these agents are active in all septic patients or just in subsets, and if 
so, whether those subgroups can be identhed pmspectively. Other 
strategies which are still at an earlier stage of development include 
the use of cytohes such as IL-10, which downregulate the in- 
flammatory response, or IL-12, which have a more subtle role in 
immunomodulation. 
lmmunomodulation for Severe Sepsis and Septic 
Shock What is the Future? 
J.L. Vincent. B 
No abstract available. 
